PURPOSE: To analyze visual outcomes in children affected by juvenile idiopathic arthritis (JIA)-associated uveitis. DESIGN: Retrospective interventional case series. PARTICIPANTS: Eighty-nine children with JIA-associated uveitis. METHODS: Charts of children with JIA-associated uveitis were reviewed. MAIN OUTCOME MEASURE: Change in patients' visual acuities (VAs). RESULTS: Of 269 children with uveitic syndromes referred, 89 (33%) had JIA-associated uveitis. The process was bilateral in 76 children. Seventy-three patients were female, and 84% of patients were Caucasian. Mean age of onset of uveitis was 5.7 years. Mean follow-up was 2.96 years. Antinuclear antibody positivity was detected in 56 patients, 44 of them female. Patients with JIA-associated uveitis developed numerous complications in the course of their disease: of 165 affected eyes, 105 (64%) developed cataracts, 33 (20%) developed increased intraocular pressure, and 76 (46%) developed band keratopathy; posterior synechiae were present in 96 (58%). Of 89 children, 73% were treated with immunomodulators, 40% were treated with nonsteroidal antiinflammatory agents alone or in combination with immunomodulators, and 21% were treated with topical and/or systemic steroids. Of 65 children who required immunomodulation, only one chemotherapeutic agent was used in 30, two agents in 21, and > or =3 in 14. Visual acuities of 65 children (122 eyes) were documented and compared at standard intervals. By mixed-models linear regression, improvement in VA of 0.03 logarithm of the minimum angle of resolution units per year was not found to be statistically significant (standard error, 0.02, P = 0.089). CONCLUSIONS: Juvenile idiopathic arthritis-associated uveitis is a sight-threatening disease. However, much of the children's vision can be preserved if patients are treated appropriately.
PURPOSE: To analyze visual outcomes in children affected by juvenile idiopathic arthritis (JIA)-associated uveitis. DESIGN: Retrospective interventional case series. PARTICIPANTS: Eighty-nine children with JIA-associated uveitis. METHODS: Charts of children with JIA-associated uveitis were reviewed. MAIN OUTCOME MEASURE: Change in patients' visual acuities (VAs). RESULTS: Of 269 children with uveitic syndromes referred, 89 (33%) had JIA-associated uveitis. The process was bilateral in 76 children. Seventy-three patients were female, and 84% of patients were Caucasian. Mean age of onset of uveitis was 5.7 years. Mean follow-up was 2.96 years. Antinuclear antibody positivity was detected in 56 patients, 44 of them female. Patients with JIA-associated uveitis developed numerous complications in the course of their disease: of 165 affected eyes, 105 (64%) developed cataracts, 33 (20%) developed increased intraocular pressure, and 76 (46%) developed band keratopathy; posterior synechiae were present in 96 (58%). Of 89 children, 73% were treated with immunomodulators, 40% were treated with nonsteroidal antiinflammatory agents alone or in combination with immunomodulators, and 21% were treated with topical and/or systemic steroids. Of 65 children who required immunomodulation, only one chemotherapeutic agent was used in 30, two agents in 21, and > or =3 in 14. Visual acuities of 65 children (122 eyes) were documented and compared at standard intervals. By mixed-models linear regression, improvement in VA of 0.03 logarithm of the minimum angle of resolution units per year was not found to be statistically significant (standard error, 0.02, P = 0.089). CONCLUSIONS:Juvenile idiopathic arthritis-associated uveitis is a sight-threatening disease. However, much of the children's vision can be preserved if patients are treated appropriately.
Authors: H Nida Sen; Lea T Drye; Debra A Goldstein; Theresa A Larson; Pauline T Merrill; Peter R Pavan; John D Sheppard; Alyce Burke; Sunil K Srivastava; Douglas A Jabs Journal: Ocul Immunol Inflamm Date: 2012-04 Impact factor: 3.070
Authors: Anna I Dastiridou; Sofia Androudi; Anna Praidou; Periklis Brazitikos; Catherine G Brozou; Evangelia E Tsironi Journal: Int Ophthalmol Date: 2012-11-16 Impact factor: 2.031
Authors: Lakshmi N Moorthy; Margaret Ge Peterson; Afton L Hassett; Thomas Ja Lehman Journal: Pediatr Rheumatol Online J Date: 2010-07-08 Impact factor: 3.054
Authors: Melissa A Lerman; Jon M Burnham; Peter Y Chang; Ebenezer Daniel; C Stephen Foster; Sean Hennessy; Douglas A Jabs; Marshall M Joffe; R Oktay Kaçmaz; Grace A Levy-Clarke; Monte D Mills; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; John H Kempen Journal: J Rheumatol Date: 2013-07-01 Impact factor: 4.666